Results 321 to 330 of about 414,727 (380)

First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial

open access: yesCancer Communications, EarlyView.
Abstract Background The ASTRUM‐005 study previously demonstrated a significant overall survival (OS) benefit with serplulimab (a programmed death 1 inhibitor) plus chemotherapy versus chemotherapy alone in previously untreated extensive‐stage small‐cell lung cancer (ES‐SCLC).
Ying Cheng   +32 more
wiley   +1 more source

Ubiquitination in cancer: mechanisms and therapeutic opportunities

open access: yesCancer Communications, EarlyView.
Abstract Ubiquitination, a key post‐translational modification, plays an essential role in tumor biology by regulating fundamental cellular processes, such as metabolism and cell death. Additionally, it interacts with other post‐translational modifications, which are closely linked to tumorigenesis, tumor progression, the tumor microenvironment, and ...
Susi Zhu   +7 more
wiley   +1 more source

Targeting SPHK1 in macrophages remodels the tumor microenvironment and enhances anti‐PD‐1 immunotherapy efficacy in colorectal cancer liver metastasis

open access: yesCancer Communications, EarlyView.
Abstract Background Colorectal cancer liver metastasis (CRLM) is characterized by an immunosuppressive microenvironment and a blunted response to immunotherapy. Notably, tumor‐associated macrophages (TAMs) play a critical role in modulating immune responses and exhibit significant heterogeneity in CRLM.
Yizhi Zhan   +11 more
wiley   +1 more source

Stereotactic body radiotherapy plus cadonilimab (PD‐1/CTLA‐4 bispecific antibody) as third‐line or beyond therapy for refractory solid tumors: A phase 1b study

open access: yesCancer Communications, EarlyView.
Abstract Background Cadonilimab is a humanized immunoglobulin G1 bispecific antibody targeting programmed cell death protein 1 (PD‐1) and cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA‐4). This study aimed to evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) combined with cadonilimab in patients with advanced recurrent or ...
Yao Xiao   +7 more
wiley   +1 more source

Lupeol‐Loaded Liposomes: Triple‐Negative Breast Cancer (TNBC) Cytotoxicity and In Vivo Toxicological Evaluation

open access: yesChemistry &Biodiversity, EarlyView.
ABSTRACT Lupeol is a natural product commonly found in many vegetables and fruits in significant quantities. Previous studies have demonstrated the relevant activity of lupeol against various tumor cell lines, suggesting that the natural product could be a promising agent for cancer treatment.
Daniel Crístian Ferreira Soares   +6 more
wiley   +1 more source

Ethnomedicinal Uses, Phytochemistry, Pharmacological Activities, and Toxicology of the Subfamily Gomphrenoideae (Amaranthaceae): A Comprehensive Review

open access: yesChemistry &Biodiversity, EarlyView.
ABSTRACT The subfamily Gomphrenoideae is composed of about 480 accepted species, many of which have been historically used as medicinal plants, reason why they have been studied in terms of chemical profile, biological activity, and safety. This review consolidates the advances in research on this subfamily over the past 47 years, emphasizing its ...
Dayanna Isabel Araque Gelves   +3 more
wiley   +1 more source

Delayed Neuropsychiatric Syndrome Due to Unrecognized Carbon Monoxide Toxicity: A Case Report

open access: yesAnnals of the Child Neurology Society, EarlyView.
ABSTRACT Introduction Carbon monoxide (CO) is a leading cause of poison‐related deaths in children and frequently results in nonspecific neurological symptoms and imaging findings. Rarely, pediatric patients develop a delayed neuropsychiatric syndrome (DNS) following a lucid interval.
Alexandria Valdrighi   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy